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Background
• Heart failure is a common and important form of heart disease in New 
Zealand with a high mortality rate. 
• The Prospective Evaluation of Outcome in Patients with Heart Failure 
with Preserved Left Ventricular Ejection Fraction (PEOPLE) study is a 
prospective study of representative patients with validated HF from four 
New Zealand hospitals. (1)
• This study investigated baseline levels of sFlt-1, a receptor for VEGF-A 
that circulates in plasma, as a prognostic marker in heart failure 
patients using samples from the PEOPLE cohort. (2-4)
• The VEGF system, including VEGF-A and sFlt-1, stimulate the 
production of new blood vessels, including collateral circulation, which 
is known to improve heart function. (5,6)
• NTproBNP is the established plasma marker for diagnosis of heart 
failure and is a strong prognostic predictor of clinical outcome in heart 
failure patients (7).
Methods
ELISA assays for sFlt-1 and NTproBNP were performed in n=858 patients 
from the PEOPLE study of outcome among patients after appropriate 
treatment for an episode of acute decompensated HF in New Zealand. 
Plasma was sampled at a baseline visit and stored at -80°C.
Results
• Mean baseline plasma sFlt-1 levels was 125 +_ 2.01 pg/ml. 
• sFlt-1 was higher in patients with HF with reduced ejection fraction 
(HFrEF) (130 +_ 2.62 pg/ml, n=553) compared to those with HF with 
preserved EF (HFpEF) (117 +_3.59 pg/ml, n=305; p=0.005) (Figure 1).
• sFlt-1 correlated with heart rate (r=0.148, p<0.001), systolic blood 
pressure (r=-0.139, p<0.001) and LVEF (r=-0.088, p=0.019).
• Above median levels of sFlt-1 were associated with increased mortality 
(p<0.001) (Figure 2). 
• Multivariate analysis using a Cox proportional hazards model showed 
sFlt-1 was a predictor of all-cause death (HR=6.30, p<0.001) in the 
PEOPLE cohort, independent of age, NTproBNP, ischaemic aetiology, 
and NYHA class (n=842; 274 deaths) and other established predictors 
of mortality in the PEOPLE cohort (Table 1). 
Table 1. 
Cox’s proportional hazards regression model for mortality in the PEOPLE 













sFlt-1 levels at baseline should be investigated further as a predictor 
of death, complementary to established prognostic biomarkers in heart 
failure.
559
df Significance Hazard Ratio
95% CI for HR
Lower Upper
NYHA class 3 0.365
NYHA I versus IV 1 0.342 0.765 0.441 1.329
NYHA II versus IV 1 0.711 0.919 0.587 1.439
NYHA III versus IV 1 0.195 0.743 0.475 1.164
Age 1 0.001 1.019 1.008 1.031
Log10 sFlt1 1 0.021 2.671 1.163 6.133
Log10 NT-proBNP 1 < 0.001 1.359 1.195 1.547
Creatinine 1 0.044 1.002 1.000 1.005
Gender 1 0.018 0.843 0.732 0.971
Beta-Blocker at  
discharge 1 0.006 1.46 0.522 0.895
Antecedent  
Hypertension 1 0.071 0.885 0.99 1.29
Antecedent diabetes 1 0.014 0.848 1.03 1.29
Figure 1a. 
Comparison of baseline sFlt-1 levels in the 
subgroups of the PEOPLE cohort defined by 
preserved and reduced ejection fraction (mean 








The Vascular Endothelial Growth 
Factor (VEGF) System. sFlt-
1 acts as a decoy receptor, 
reducing the binding of VEGF to 
membrane-bound Flt-1 and KDR, 
down-regulating stimulation of 
angiogenesis.  
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Figure 2. 
Kaplan-Meier survival curve of the PEOPLE cohort stratified by above and 
below median baseline sFlt-1 levels.
Events
sFlt-1 below median   435 404 301 193    102 18 112 (25.7%)
sFlt-1 above median   423 349 253 161 89 8 166 (39.2%)
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